Sunitinib is a first‐line treatment agent for advanced RCC and functions as an oral multitarget receptor Tyrosine kinase inhibitors that specifically inhibits signaling pathways involving vascular endothelial growth factor and platelet‐derived growth factor receptor. This evidence concerns the gene VEGFA and renal cell carcinoma.